Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.

Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA.

Cancer Discov. 2017 Dec;7(12):1464-1479. doi: 10.1158/2159-8290.CD-17-0539. Epub 2017 Sep 11.


Metabolic reprogramming in clear cell renal cell carcinoma.

Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH.

Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Review.


Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH.

Cancer Res. 2015 Jun 15;75(12):2541-52. doi: 10.1158/0008-5472.CAN-14-1703. Epub 2015 May 7.


Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH.

PLoS One. 2014 Dec 2;9(12):e113867. doi: 10.1371/journal.pone.0113867. eCollection 2014.


Biological evaluation of a novel sorafenib analogue, t-CUPM.

Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD.

Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21.


Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.

Tan M, Wettersten HI, Chu K, Huso DL, Watnick T, Friedlander S, Landesman Y, Weiss RH.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1179-86. doi: 10.1152/ajprenal.00406.2014. Epub 2014 Sep 18.


Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11127-32. doi: 10.1073/pnas.1410432111. Epub 2014 Jul 14.


Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A.

Gupta R, Dong Y, Solomon PD, Wettersten HI, Cheng CJ, Min JN, Henson J, Dogra SK, Hwang SH, Hammock BD, Zhu LJ, Reddel RR, Saltzman WM, Weiss RH, Chang S, Green MR, Wajapeyee N.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. doi: 10.1073/pnas.1411370111. Epub 2014 Jul 14.


Metabolomic profiling of tumor-bearing mice.

Wettersten HI, Ganti S, Weiss RH.

Methods Enzymol. 2014;543:275-96. doi: 10.1016/B978-0-12-801329-8.00014-3.


Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL 3rd, Gomes AV, Baar K, Weiss RH, Hammock BD.

Anticancer Drugs. 2014 Apr;25(4):433-46. doi: 10.1097/CAD.0000000000000079.


Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment.

Kim K, Mall C, Taylor SL, Hitchcock S, Zhang C, Wettersten HI, Jones AD, Chapman A, Weiss RH.

PLoS One. 2014 Jan 24;9(1):e86223. doi: 10.1371/journal.pone.0086223. eCollection 2014.


Inhibition of PPAR╬▒ induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.

Abu Aboud O, Wettersten HI, Weiss RH.

PLoS One. 2013 Aug 7;8(8):e71115. doi: 10.1371/journal.pone.0071115. eCollection 2013.


Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.

Liu R, Wettersten HI, Park SH, Weiss RH.

Future Med Chem. 2013 Jun;5(9):991-4. doi: 10.4155/fmc.13.56. No abstract available.


Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.

Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6530-5. doi: 10.1073/pnas.1304321110. Epub 2013 Apr 3.


Potential biofluid markers and treatment targets for renal cell carcinoma.

Wettersten HI, Weiss RH.

Nat Rev Urol. 2013 Jun;10(6):336-44. doi: 10.1038/nrurol.2013.52. Epub 2013 Apr 2. Review.


Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets.

Wettersten HI, Weiss RH.

Organogenesis. 2013 Jan-Mar;9(1):11-8. doi: 10.4161/org.24322. Epub 2013 Jan 1. Review.


From bead to flask: Synthesis of a complex ╬▓-amido-amide for probe-development studies.

Martin KS, Soldi C, Candee KN, Wettersten HI, Weiss RH, Shaw JT.

Beilstein J Org Chem. 2013;9:260-4. doi: 10.3762/bjoc.9.31. Epub 2013 Feb 6.


A novel p21 attenuator which is structurally related to sorafenib.

Wettersten HI, Hee Hwang S, Li C, Shiu EY, Wecksler AT, Hammock BD, Weiss RH.

Cancer Biol Ther. 2013 Mar;14(3):278-85. doi: 10.4161/cbt.23374. Epub 2013 Jan 8.

Supplemental Content

Loading ...
Support Center